公司資料
Monte Rosa Therapeutics 股價、新聞與催化劑
- 股票代碼:
- GLUE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
15.38 USD (-0.77%)
收盤價
最後更新: 2026年8月17日
1.5B USD
市值
股價為何變動
As of Aug 17, 2026, GLUE closed down 0.77% at $15.38. No new same-company headline was identified in the current news window.
公司概覽
Molecular Glue Degraders
Monte Rosa Therapeutics develops small-molecule molecular glues that redirect cellular machinery to degrade disease-causing proteins. The platform is intended to address targets that are difficult to inhibit conventionally.
MRT-8102
MRT-8102 is a NEK7-directed molecular glue degrader being developed for inflammatory and cardiometabolic diseases. Clinical work includes cardiovascular-risk, gout and hidradenitis-suppurativa populations.
MRT-2359 and Oncology Pipeline
MRT-2359 targets GSPT1 and is being evaluated with androgen-receptor inhibitors in metastatic castration-resistant prostate cancer.
Cyclin E1 Program
Monte Rosa is preparing a selective cyclin E1-directed molecular glue degrader for clinical development in tumors driven by cyclin E dysregulation.
未來催化劑
- Initiation of a Phase 2 cardiovascular-risk study of MRT-8102 in the second half of 2026.
- Expanded GFORCE-1 data for MRT-8102 in the second half of 2026.
- Initiation of a Phase 2 study of MRT-2359 plus apalutamide in the third quarter of 2026.
- IND submission for the cyclin E1 degrader in the second half of 2026.
- Initiation of MRT-8102 Phase 2 studies in gout in the fourth quarter of 2026 or first quarter of 2027 and in hidradenitis suppurativa in the first half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。